Kissling, EstherRose, Angela McEmborg, Hanne-DortheGherasim, Alin ManuelPebody, RichardPozo Sanchez, FranciscoTrebbien, RamonaMazagatos, ClaraWhitaker, HeatherValenciano, MartaEuropean IVE groupLarrauri, AmparoCasas Flecha, InmaculadaDelgado-Sanz, ConcepcionOliva Dominguez, Jesus Angel2020-01-292020-01-292019Euro Surveill. 2019 Feb;24(8):1900121.1560-7917http://hdl.handle.net/20.500.12105/8980Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.engVoRhttp://creativecommons.org/licenses/by/4.0/EuropeInfluenzaMulticentre studyTest-negative designVaccinationVaccine effectivenessVaccines and immunisationAtribución 4.0 Internacional3080844024810.2807/1560-7917.ES.2019.24.19001211560-7917Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinopen access